122 related articles for article (PubMed ID: 12001116)
1. Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma.
Salvesen HB; Stefansson I; Kalvenes MB; Das S; Akslen LA
Cancer; 2002 Apr; 94(8):2185-91. PubMed ID: 12001116
[TBL] [Abstract][Full Text] [Related]
2. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
3. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma.
Salvesen HB; MacDonald N; Ryan A; Jacobs IJ; Lynch ED; Akslen LA; Das S
Int J Cancer; 2001 Jan; 91(1):22-6. PubMed ID: 11149415
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
5. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis.
Martini M; Ciccarone M; Garganese G; Maggiore C; Evangelista A; Rahimi S; Zannoni G; Vittori G; Larocca LM
Int J Cancer; 2002 Dec; 102(4):398-406. PubMed ID: 12402310
[TBL] [Abstract][Full Text] [Related]
6. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.
Tashiro H; Blazes MS; Wu R; Cho KR; Bose S; Wang SI; Li J; Parsons R; Ellenson LH
Cancer Res; 1997 Sep; 57(18):3935-40. PubMed ID: 9307275
[TBL] [Abstract][Full Text] [Related]
7. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
[TBL] [Abstract][Full Text] [Related]
8. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome.
Peiró G; Lohse P; Mayr D; Diebold J
Am J Clin Pathol; 2003 Jul; 120(1):78-85. PubMed ID: 12866376
[TBL] [Abstract][Full Text] [Related]
10. PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status.
Kappes H; Goemann C; Bamberger AM; Löning T; Milde-Langosch K
Pathobiology; 2001; 69(3):136-42. PubMed ID: 11872959
[TBL] [Abstract][Full Text] [Related]
11. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
Salvesen HB; Stefansson I; Kretzschmar EI; Gruber P; MacDonald ND; Ryan A; Jacobs IJ; Akslen LA; Das S
Int J Oncol; 2004 Dec; 25(6):1615-23. PubMed ID: 15547698
[TBL] [Abstract][Full Text] [Related]
12. Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas.
Bąkiewicz A; Michalak J; Sporny S
Pol J Pathol; 2010; 61(4):185-91. PubMed ID: 21290340
[TBL] [Abstract][Full Text] [Related]
13. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration.
Marsit CJ; Zheng S; Aldape K; Hinds PW; Nelson HH; Wiencke JK; Kelsey KT
Hum Pathol; 2005 Jul; 36(7):768-76. PubMed ID: 16084946
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
[TBL] [Abstract][Full Text] [Related]
15. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer.
Terakawa N; Kanamori Y; Yoshida S
Endocr Relat Cancer; 2003 Jun; 10(2):203-8. PubMed ID: 12790783
[TBL] [Abstract][Full Text] [Related]
16. [Correlations of p-AKT with PTEN, P53, HER-2 expressions in endometrial carcinoma and their relationship with patient survival].
Zhang XM; Liang Y; Dong Y; Zhang Y; Wang Y; Meng YT; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 44(1):135-41. PubMed ID: 22353917
[TBL] [Abstract][Full Text] [Related]
17. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma.
Uegaki K; Kanamori Y; Kigawa J; Kawaguchi W; Kaneko R; Naniwa J; Takahashi M; Shimada M; Oishi T; Itamochi H; Terakawa N
Oncol Rep; 2005 Aug; 14(2):389-92. PubMed ID: 16012720
[TBL] [Abstract][Full Text] [Related]
18. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutations of the PTEN/NMAC1 gene associated with frequent chromosomal loss detected using comparative genomic hybridization in endometrial cancer.
Hirai Y; Tanaka N; Furuta R; Kawaguchi T; Sakamoto M; Shirahama S; Noda T
Gynecol Oncol; 2001 Oct; 83(1):81-8. PubMed ID: 11585417
[TBL] [Abstract][Full Text] [Related]
20. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases.
Bussaglia E; del Rio E; Matias-Guiu X; Prat J
Hum Pathol; 2000 Mar; 31(3):312-7. PubMed ID: 10746673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
